Clinical Trials Directory

Trials / Completed

CompletedNCT01914965

Apathy Cure Through Bupropion in Huntington's Disease

A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Charite University, Berlin, Germany · Academic / Other
Sex
All
Age
25 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I \[informant\] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten (10) weeks of treatment.

Detailed description

The safety and tolerability of Bupropion in HD. The influence of Bupropion compared to placebo on the: * change of apathy as quantified by the AES-C (clinician) or the AES-S (self), * change of motor symptoms (UHDRS) and quantitative grip force motor assessment, * change of cognitive symptoms (UHDRS and MMSE), * change of psychiatric symptoms (UHDRS, HADS), * change of activities of daily living (UHDRS), * change of the NPI caregivers' distress score (NPI-D), * change of ventral striatal and ventromedial prefrontal activation in response to a reward paradigm as quantified by fMRI.

Conditions

Interventions

TypeNameDescription
DRUGBupropionCrossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
DRUGPlaceboCrossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days

Timeline

Start date
2012-06-01
Primary completion
2014-05-01
Completion
2014-05-01
First posted
2013-08-02
Last updated
2014-09-09

Locations

2 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT01914965. Inclusion in this directory is not an endorsement.